---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-000344"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T01:36:20.613525+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alnylam Q4 2022 product revenue $262M (+35% YoY); guides 2023 revenue $1.2-1.285B

## Summary
- Q4 2022 net product revenue $262M; full year $894M (+35% YoY). GAAP net loss $1.13B for 2022 vs $853M in 2021.
- ONPATTRO Q4 rev $122M, AMVUTTRA $69M; total TTR rev $651M for 2022 (+37% YoY).
- sNDA for ONPATTRO in ATTR cardiomyopathy accepted by FDA; PDUFA date Oct 8, 2023; advisory committee planned.
- 2023 guidance: combined net product revenue $1.2B-$1.285B; collaboration and royalty revenue also guided.
- Cash $2.19B at year-end; appointed Carolyn Bertozzi to board; Amy Schulman becomes Chair.

## SEC filing metadata
- accession: 0001157523-23-000344
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000115752323000344/0001157523-23-000344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000115752323000344/a53337940.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-000344
- JSON: https://secwatch.observer/filing/0001157523-23-000344.json
- Plain text: https://secwatch.observer/filing/0001157523-23-000344.txt

## Key facts
- Earnings Releases
  ALNYLAM PHARMACEUTICALS, INC. reported the year ending December 31, 2023 results: revenue $1,200 Million to $1,285 Million. Guidance initiated.
  - Period: the year ending December 31, 2023
  - Revenue: $1,200 Million to $1,285 Million
  - Guidance: initiated
  - Result: guidance update
  source text: Provides 2023 Combined Net Product Revenue Guidance of $1,200 Million to $1,285 Million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000115752323000344/0001157523-23-000344-index.htm
- Earnings Releases
  ALNYLAM PHARMACEUTICALS, INC. reported the year ended December 31, 2022 results: revenue $894 Million.
  - Period: the year ended December 31, 2022
  - Revenue: $894 Million
  - Result: reported results
  source text: Achieved Fourth Quarter and Full Year 2022 Global Net Product Revenues of $262 Million and $894 Million, Respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000115752323000344/0001157523-23-000344-index.htm
- Earnings Releases
  ALNYLAM PHARMACEUTICALS, INC. reported the quarter ended December 31, 2022 results: revenue $262 Million.
  - Period: the quarter ended December 31, 2022
  - Revenue: $262 Million
  - Result: reported results
  source text: Achieved Fourth Quarter and Full Year 2022 Global Net Product Revenues of $262 Million and $894 Million, Respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000115752323000344/0001157523-23-000344-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.